About Minerva Neurosciences
Minerva Neurosciences is a company based in Waltham (United States) founded in 2007 was acquired by Royalty Pharma in January 2021.. The company has 8 employees as of December 31, 2024. Minerva Neurosciences has completed 1 acquisition, including Mind-NRG. Minerva Neurosciences offers products and services including Roluperidone, MIN-301, and Seltorexant. Minerva Neurosciences operates in a competitive market with competitors including Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 8 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Minerva Neurosciences, Inc
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$1.44 M0as on Dec 31, 2024
-
EBITDA
$-21.83 M5.47as on Dec 31, 2024
-
Latest Funding Round
$200 M (USD), Post-IPO
Oct 21, 2025
-
Investors
SVB
& 4 more
-
Employee Count
8
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Royalty Pharma
(Jan 21, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Minerva Neurosciences
Minerva Neurosciences is a publicly listed company on the NASDAQ with ticker symbol NERV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Minerva Neurosciences
Minerva Neurosciences offers a comprehensive portfolio of products and services, including Roluperidone, MIN-301, and Seltorexant. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment candidate for schizophrenia symptoms
Potential therapy for Parkinson's disease
Drug for central nervous system disorders
Unlock access to complete
Unlock access to complete
Funding Insights of Minerva Neurosciences
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $200.0M
-
First Round
First Round
(20 Jan 2015)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Post-IPO - Minerva Neurosciences | Valuation |
investors |
|
| Jun, 2023 | Amount | Post-IPO - Minerva Neurosciences | Valuation |
investors |
|
| Mar, 2016 | Amount | Post-IPO - Minerva Neurosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Minerva Neurosciences
Minerva Neurosciences has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Boehringer Ingelheim and Royalty Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Founded Year | Domain | Location | |
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Founded Year | Domain | Location | |
|
Generic drugs and clinical research services are provided globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Minerva Neurosciences
Minerva Neurosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Mind-NRG. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Peptidic neurotrophic factors for CNS diseases are developed by Mind-NRG.
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Minerva Neurosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Minerva Neurosciences Comparisons
Competitors of Minerva Neurosciences
Minerva Neurosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| domain | founded_year | HQ Location |
Therapies for central nervous system diseases and pain are developed.
|
|
| domain | founded_year | HQ Location |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
|
| domain | founded_year | HQ Location |
Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology.
|
|
| domain | founded_year | HQ Location |
Pasithea is focused on developing treatments for neurological disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Minerva Neurosciences
Frequently Asked Questions about Minerva Neurosciences
When was Minerva Neurosciences founded?
Minerva Neurosciences was founded in 2007 and raised its 1st funding round 8 years after it was founded.
Where is Minerva Neurosciences located?
Minerva Neurosciences is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
How many employees does Minerva Neurosciences have?
As of Dec 31, 2024, the latest employee count at Minerva Neurosciences is 8.
What does Minerva Neurosciences do?
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minervas proprietary compounds include: MIN-101, in Phase 2B development for schizophrenia; MIN-202 (JNJ-42847922), in Phase 2A and Phase 1B development for insomnia and adjunctive treatment of MDD, respectively; MIN-117, in Phase 2A development for MDD; and MIN-301, in pre-clinical development for Parkinsons disease.
Who are the top competitors of Minerva Neurosciences?
Minerva Neurosciences's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
What products or services does Minerva Neurosciences offer?
Minerva Neurosciences offers Roluperidone, MIN-301, and Seltorexant.
Is Minerva Neurosciences publicly traded?
Yes, Minerva Neurosciences is publicly traded on NASDAQ under the ticker symbol NERV.
How many acquisitions has Minerva Neurosciences made?
Minerva Neurosciences has made 1 acquisition, including Mind-NRG.
Who are Minerva Neurosciences's investors?
Minerva Neurosciences has 5 investors. Key investors include SVB, Boehringer Ingelheim, Royalty Pharma, Oxford Finance, and Federated Hermes.
What is Minerva Neurosciences's ticker symbol?
The ticker symbol of Minerva Neurosciences is NERV on NASDAQ.